UY29600A1 - Nuevos heterociclos como inhibidores de trombina, composiciones farmacéuticas que los contienen, procedimientos para su preparación y aplicaciones - Google Patents

Nuevos heterociclos como inhibidores de trombina, composiciones farmacéuticas que los contienen, procedimientos para su preparación y aplicaciones

Info

Publication number
UY29600A1
UY29600A1 UY29600A UY29600A UY29600A1 UY 29600 A1 UY29600 A1 UY 29600A1 UY 29600 A UY29600 A UY 29600A UY 29600 A UY29600 A UY 29600A UY 29600 A1 UY29600 A1 UY 29600A1
Authority
UY
Uruguay
Prior art keywords
heterocicles
procedures
applications
preparation
new
Prior art date
Application number
UY29600A
Other languages
English (en)
Inventor
Magnus Polla
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29600A1 publication Critical patent/UY29600A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto de fórmula I en donde R1, R2a, R2b, R3a, R3b, R4, R5a, R5b, R6 a R8, A y G tienen los significados que se proporcionan en la descripción, cuyos compuestos resultan útiles como, o son útiles como profármacos de, inhibidores competitivos de proteasas similares a tripsina, como trombina, y por tanto, en particular, en el tratamiento de afecciones en las que la inhibición de trombina resulta beneficiosa (por ej.condiciones, como tromboembolismos, en los que se requiera o desee la inhibición de trombina, y/o afecciones en las que se indique terapia anticoagulante).
UY29600A 2005-06-17 2006-06-14 Nuevos heterociclos como inhibidores de trombina, composiciones farmacéuticas que los contienen, procedimientos para su preparación y aplicaciones UY29600A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501413 2005-06-17

Publications (1)

Publication Number Publication Date
UY29600A1 true UY29600A1 (es) 2007-01-31

Family

ID=37532584

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29600A UY29600A1 (es) 2005-06-17 2006-06-14 Nuevos heterociclos como inhibidores de trombina, composiciones farmacéuticas que los contienen, procedimientos para su preparación y aplicaciones

Country Status (18)

Country Link
US (1) US20080207695A1 (es)
EP (1) EP1893601A1 (es)
JP (1) JP2008546684A (es)
KR (1) KR20080021145A (es)
CN (1) CN101243069A (es)
AR (1) AR054512A1 (es)
AU (1) AU2006258300A1 (es)
BR (1) BRPI0612045A2 (es)
CA (1) CA2610428A1 (es)
EC (1) ECSP088111A (es)
IL (1) IL187580A0 (es)
MX (1) MX2007016090A (es)
NO (1) NO20076071L (es)
RU (1) RU2007146731A (es)
TW (1) TW200738675A (es)
UY (1) UY29600A1 (es)
WO (1) WO2006135323A1 (es)
ZA (1) ZA200710564B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN113698386B (zh) * 2020-05-22 2022-12-27 上海美悦生物科技发展有限公司 一种4(1h)-吡啶酮类化合物、其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503161A (ja) * 1995-04-04 1999-03-23 メルク エンド カンパニー インコーポレーテッド トロンビン阻害剤
CA2224437A1 (en) * 1995-06-27 1997-01-16 Merck & Co., Inc. Pyridinone-thrombin inhibitors
JP3140790B2 (ja) * 1996-04-23 2001-03-05 メルク エンド カンパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
US5668289A (en) * 1996-06-24 1997-09-16 Merck & Co., Inc. Pyridinone thrombin inhibitors
US5792779A (en) * 1997-02-19 1998-08-11 Merck & Co., Inc. Pyridinone thrombin inhibitors
US5866573A (en) * 1997-04-21 1999-02-02 Merck & Co., Inc. Pyrazinone thrombin inhibitors
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
AU2002246675A1 (en) * 2000-12-18 2002-07-30 Merck And Co., Inc. Thrombin inhibitors
US6946283B2 (en) * 2001-01-05 2005-09-20 William Marsh Rice University Ginkgo biloba levopimaradiene synthase
WO2002064140A1 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
SI21097A (sl) * 2001-12-04 2003-06-30 Univerza V Ljubljani Inhibitorji trombina
AR047521A1 (es) * 2004-02-06 2006-01-25 Astrazeneca Ab Compuestos piridin-2-ona utiles como inhibidores de trombina

Also Published As

Publication number Publication date
TW200738675A (en) 2007-10-16
MX2007016090A (es) 2008-03-10
JP2008546684A (ja) 2008-12-25
WO2006135323A1 (en) 2006-12-21
IL187580A0 (en) 2008-03-20
EP1893601A1 (en) 2008-03-05
ECSP088111A (es) 2008-02-20
AR054512A1 (es) 2007-06-27
ZA200710564B (en) 2008-11-26
NO20076071L (no) 2008-01-08
RU2007146731A (ru) 2009-07-27
US20080207695A1 (en) 2008-08-28
CA2610428A1 (en) 2006-12-21
BRPI0612045A2 (pt) 2018-07-24
KR20080021145A (ko) 2008-03-06
CN101243069A (zh) 2008-08-13
AU2006258300A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
ECSP10010015A (es) Inhibidores de proteasoma
UY30748A1 (es) Compuesto0s novedosos
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CO6680683A2 (es) Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
CU20090209A7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
CR20120529A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
GT200600117A (es) Nuevos compuestos farmaceuticos
UY33779A (es) ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
GT200500287A (es) Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CR20110309A (es) Compuestos orgánicos
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
CR10479A (es) Modulares bencimidazolicos de vr1
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
CO6331434A2 (es) Nuevos compuestos
AR067140A2 (es) Nuevo procedimiento de tratamiento de frutas o legumbres mediante el ion fosforoso y las composiciones correspondientes

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160817